Sinonasal malignant tumor
Conditions
Interventions
treatment group:induction chemotherapy-surgery – radiotherapy-adjuvant chemotherapy
control group:surgery – radiotherapy-adjuvant chemotherapy
Sponsors
Beijing TongRen Hospital, Capital Medicine University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pathological diagnosis of rhabdomyomasquamous cell carcinoma and olfactory neuroblastoma; 2. Primary Sinonasal (nasal cavityparanasal sinus and nasopharynx); 3. Patients without treatment before (primary, no history of surgery, radiotherapy and chemotherapy); 4. III and IV stage (AJCC 2010); 5. at least the orbital wall was invaded on the Imaging examinations; 6. Aged 16-70 years old; 7. KPS score =80; 8. Blood routine examination, main organs such as heart, lung, liver and kidney function is almost normal. WBC=3.5×10^9/L, ANC =1.5×10^9/L, PLT=100×10^9/L, Hb=80g/L, serum total bilirubin =1.5×normal value upper limit, ALT, AST, or AKP =2.5×normal value upper limit, urea nitrogen, creatinine=1.25 x normal value upper limit; 9. Patients should sign the informed consent and follow the doctor's advice.
Exclusion criteria
Exclusion criteria: 1. Primary diagnosed distant metastasis; 2. Primary ocular tumors; 3. pregnant or lactating women; 4. serious and uncontrollable infection; 5. With other serious diseasesmay lead to greater risk or compliance with the testfor exampleActive Tuberculosis unstable heart, liver or kidney diseasesmental disease other malignant tumors; 6. The ones who researchers did not consider the case of the appropriate group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eye function;Survival prognostic index; | — |
Countries
China
Contacts
Public ContactXiaohong Chen
Beijing TongRen Hospital, Capital Medicine University
Outcome results
None listed